Abstract:Obesity, the major cause of the current global epidemic of type 2 diabetes (T2D), induces insulin resistance in peripheral insulin target tissues. Several mechanisms have been identified related to cross-talk between adipose tissue, skeletal muscle and liver. These mechanisms involve both increased free fatty acid release and altered secretion of adipokines from adipose tissue. A major determinant of metabolic health is the ability of subcutaneous adipose tissue (SAT) to store excess fat rather than allowing it to accumulate in ectopic depots including liver (i.e. in nonalcoholic fatty liver disease), muscle and heart, or in epicardial/pericardial and visceral fat depots which promote the metabolic complications of obesity. The ability to recruit and differentiate precursor cells into adipose cells (adipogenesis) in SAT is under genetic regulation and is reduced in high-risk individuals who have first-degree relatives with T2D. Early recruitment of new adipose cells is dependent on the cross-talk between canonical WNT and BMP4 signalling; WNT enhances their undifferentiated and proliferative state whereas BMP4 induces their commitment to the adipogenic lineage. Dysregulation of these signalling pathways is associated with impaired adipogenesis and impaired ability to respond to the need to store excess lipids in SAT. This leads to hypertrophic, dysfunctional and insulin-resistant adipose cells with a reduced content of GLUT4, the major insulin-regulated glucose transporter, which in turn reduces adipose tissue glucose uptake and de novo lipogenesis. We recently identified that reduced GLUT4 and lipogenesis in adipocytes impairs the synthesis of a novel family of lipids secreted by adipose tissue (and potentially other tissues), branched fatty acid esters of hydroxy fatty acids (FAHFAs). FAHFAs have beneficial metabolic effects, including enhancing insulin-stimulated glucose transport and glucose-stimulated GLP1 and insulin secretion, as well as powerful anti-inflammatory effects. FAHFA levels are reduced in subcutaneous adipose tissue in insulin-resistant individuals, and this novel family of lipids may become of future therapeutic use.

Adipose Tissue Plasticity and Insulin Signaling in the Pathogenesis of Type 2 Diabetes

Adipose Tissue Dynamics, Thermogenesis, and Interorgan Connections for Preventing Obesity and Metabolic Disorders

Adipose Tissue-Resident Immune Cells in Obesity and Type 2 Diabetes

Adipose Signals Regulating Distal Organ Health and Disease

Tissue-specific activation of insulin signaling as a potential target for obesity-related metabolic disorders

Type 2 Immune Regulation of Adipose Tissue Homeostasis

Adipose Tissue and Metabolic Health

Adipose tissue regulates insulin sensitivity: role of adipogenesis, de novo lipogenesis and novel lipids

Adipose-tissue plasticity in health and disease

Targeting adipose tissue in the treatment of obesity-associated diabetes

Adipose Tissue Dysfunction as Determinant of Obesity-Associated Metabolic Complications

Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease

Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes

The mechanisms linking adiposopathy to type 2 diabetes

Adipose Tissue-Specialized Immunologic Features Might Be the Potential Therapeutic Target of Prospective Medicines for Obesity

Recent advances in the effect of adipose tissue inflammation on insulin resistance

Adipose Tissue Dysfunction Determines Lipotoxicity and Triggers the Metabolic Syndrome: Current Challenges and Clinical Perspectives

Adipose Tissue Plasticity: A Comprehensive Definition and Multidimensional Insight

The integrative biology of type 2 diabetes

Adipose Tissue Inflammation and Metabolic Dysfunction in Obesity.

Adipose Tissue Macrophage Phenotypes and Characteristics: the Key to Insulin Resistance in Obesity and Metabolic Disorders